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Review Article 
Adjuvant Therapy for the Reduction of Postoperative
Intra-abdominal Adhesion Formation
Jason PY Cheung, Helen HL Tsang, Janice JC Cheung, Harry HY Yu, Gilberto KK Leung and Wai Lun Law,
Department of Surgery, University of Hong Kong Medical Centre, Queen Mary Hospital, Hong Kong.
BACKGROUND: To review currently available evidence on the use of adjuvant therapy to reduce the 
formation of postoperative intra-abdominal adhesions.
METHODS: A search on Pubmed and the Cochrane library was undertaken using the keywords 
“abdominal”, “adhesion”, “postoperative”, “prevention” and “reduction”. Only randomised controlled
trials, prospective non-randomised controlled studies and review articles published in the English 
language between 1990 and 2006 were included.
RESULTS: Two prospective non-randomised controlled studies and 18 randomised controlled trials were
included in this review. Adjuvant therapies reviewed included pharmacological agents (streptokinase,
recombinant tissue plasminogen activator, vitamin E antioxidant molecules), and mechanical barriers
(hyaluronic acid barriers, oxidised regenerated cellulose barriers, nanofibrous barriers and collagen foils).
Hyaluronate/carboxymethylcellulose-based bioresorbable membrane (Seprafilm) appeared to be the most
efficacious in reducing adhesion formation as well as decreasing the incidence of adhesion obstruction
requiring reoperation in clinical studies. Drawbacks to the use of Seprafilm include high cost and 
complications such as haemorrhage and poor wound healing.
CONCLUSIONS: Only a limited number of adjuvant treatment methods are currently available for the
reduction of postoperative adhesions. Seprafilm has been proven to be the efficacious method to reduce
adhesions. Investigations into the novel therapies are showing promising results in experimental studies
and clinical studies before their wider application. [Asian J Surg 2009;32(3):180–6]
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Introduction
Peritoneal adhesion formation after abdominal and
pelvic operations is common and this can be a source 
of considerable morbidity. The incidence of intraperi-
toneal adhesions ranges from 67 to 93% after general sur-
gical abdominal operations and up to 97% following 
open gynaecological pelvic procedures.1 Adhesions form
between the wound and the omentum in over 80% of
patients and these adhesions may involve the intestines 
in 50% of patients.1 One of the most serious consequences
of adhesion formation is small bowel obstruction. In the
United States, up to 70% of small bowel obstructions 
are due to adhesions.2 Within 2 years of surgery, 14% of
patients may develop adhesive intestinal obstruction.3
After a first episode, 53% of patients would go on to
develop a second episode of adhesive obstruction, and
83% of these would have chronic symptoms.3 The inci-
dence of small bowel obstruction has been reported 
to be as high as 10% after appendectomy, 6.4% after 
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open cholecystectomy, and 10 to 25% after intestinal sur-
gery.4 The workload and costs associated with bowel
obstruction caused by postoperative adhesions are sub-
stantial. Hence, there is an important need to prevent or
minimise the formation of postoperative intra-abdominal
adhesion.
Surgical trauma to the mesothelial surface of the peri-
toneum exposes the submesothelial matrix and initiates a
process of healing. The coagulation cascade is activated,
resulting in fibrin deposition and subsequently fibrinoly-
sis. When there is an imbalance in favour of fibrin deposi-
tion, bridges between various unrelated tissue surfaces
may develop and adhesions will be formed.5 Factors asso-
ciated with this imbalance include surgical trauma, infec-
tion, ischaemia and exposure to foreign materials, such as
talc and glove powder, lint from abdominal packs, and
fibres from disposable paper items.1,6,7
The main approaches to prevent adhesion formation
include the adjustment of surgical techniques, avoidance
of foreign material exposure, and the applications of
adjuvant treatment.1,6,7 Other effective measures include
careful tissue handling, keeping tissues moist, and the use
of micro- and atraumatic instruments to reduce serosal
injury.8 The target of most anti-adhesion therapies is the
fibrin gel matrix.1,6,7 Applying an agent intra-abdominally
at the time of operation bypasses the difficulties of thera-
peutic homing and minimises potential systemic side
effects. The time window for a successful intervention is
relatively small (5 to 7 days).6 An optimal adhesive barrier
should be non-toxic, biocompatible, easy to apply, and is
ideally dissolved after 1 to 2 weeks.6 In general, adjuvant
therapy falls into two main categories. The first is the
administration of drugs that prevent excessive fibrin 
deposition. The second is the separation of serosal sur-
faces during the early stages of wound healing by means
of mechanical barriers.9
This review will focus on pharmacological and barrier
adjuvant therapies for preventing or reducing the forma-
tion of postoperative intra-abdominal adhesions. The
authors aim to review available evidence on different
forms of treatment currently in use as well as novel thera-
pies that are still in the experimental stages.
Methods
A literature search using electronic databases, including
PubMed and the Cochrane library was performed. Search
terms included “abdominal”, “adhesion”, “postoperative”,
“prevention” and “reduction”. Two independent investi-
gators screened the abstracts of articles. The inclusion cri-
teria were: (i) randomised controlled trials or prospective
non-randomised controlled studies or reviews published
in the English language between 1990 and 2006; (ii) arti-
cles describing adjuvant therapy for the prevention of
intestinal adhesion formation after abdominal or pelvic
surgery; (iii) animal experiments or clinical studies. Bibli-
ographies of review articles were searched for potentially
relevant studies not identified through the electronic
searches. Two independent investigators undertook the
data extraction from these articles.
A total of two prospective non-randomised controlled
studies and 18 randomised controlled trials were identi-
fied (Table 1). Adjuvant therapy for the reduction of adhe-
sion formation may be classified into pharmacological
and mechanical barrier methods. Table 2 lists the main
modalities of treatment which are to be discussed in the
following sections.
Results
Pharmacological adjuvant therapy
Streptokinase
Streptokinase enhances fibrinolysis by increasing the con-
version of plasminogen to plasmin, and thereby reduces
excessive fibrin deposition which is the key event in adhe-
sion formation. Results from experimental animal stud-
ies were, however, disappointing.10,11 Several factors may
limit the application of pharmacological agents in pre-
venting adhesion formation. Firstly, ischaemic sites liable
to adhesion formation are cut off from systemic drug
delivery. Secondly, the peritoneum rapidly absorbs and
reduces the efficacy of any intraperitoneally administered
agents. Thirdly, anti-adhesion agents may affect normal
wound healing.1 A fibrinolytic activity lasting for a mini-
mum of 2 days is needed for the prevention of adhesion
formation.12 The plasma clearance time for streptokinase
is 23 minutes and it is expected to completely disappear
from the peritoneal cavity after 6 hours.13 Simply admin-
istrating streptokinase intraperitoneally therefore showed
no significant effect on the prevention of postoperative
adhesions.13
Repeated injections of fibrinolytic agents or controlled
release of them with an infusion pump have been investi-
gated in animal models. It was shown that prolonged
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exposure of the peritoneal cavity to streptokinase decreased
postoperative adhesion formation.13 Yagmurlu et al showed
in the rat model that continuous use of streptokinase 
was shown to prevent postoperative adhesion formation
in 90% of cases.13 Biodegradable drug delivery systems
such as polyhydroxybutyrate-co-hydroxyvalerate (PHBV)
membranes can deliver the streptokinase continuously
and had been shown to reduce the extent and severity of
the developed adhesions. A lower dose of streptokinase
was needed to minimise the harmful side effects such as 
postoperative haemorrhages.13
Recombinant tissue plasminogen activator
Tissue plasminogen activator (t-PA) converts the inactive
proenzyme plasminogen into active plasmin, which in
turn degrades the fibrin matrix structure. Alteplase or
recombinant human tissue plasminogen activator (rt-PA)
has several advantages over previously used thrombolytic
agents. Animal studies with Alteplase found that the
agent did not cause immunogenic reactions,11,14 and was
readily absorbed into fibrin clots and displayed their
effect locally.11,14 The incidence of adhesion was less than
31% as compared to 57.2% in the control group.11 There
is a dose-related treatment effect. A further reduction in
adhesion formation was found with increasing dosages of
rt-PA.11 There was also a reduction in adhesions from
13.1% after 1 day to 6.9% after 4 days of use.11 The risk of
complications, such as bleeding, systemic fibrinogenoly-
sis and impaired wound healing, was not assessed in the
Table 1. Studies reviewed
Authors Type Subjects Therapy studied
Beck 200329 RCT Human Seprafilm
Beck 19979 RCT Human Seprafilm
Becker 199625 RCT Human Hyaluronic acid barrier
Burns 199519 RCT Animal Sepracoat
Cohen 200528 RCT Animal Seprafilm
de la Portilla F 200416 RCT Animal Vitamin E antioxidant
Diamond 199121 RCT Animal Interceed
Diamond 199623 RCT Animal Seprafilm
Diamond 199820 RCT Human Sepracoat
Dunn 199311 RCT Animal Recombinant t-PA
Fazio 200627 RCT Human Seprafilm
Menzies 199112 RCT Animal Recombinant t-PA
Schonleben 200617 RCT Animal Collagenfoil
Tang 20053 RCT Human Hyaluronic acid barrier
Urman 199118 RCT Animal Sepracoat
Vrijland 200226 RCT Human Seprafilm
Yagmurlu 200313 RCT Animal Streptokinase
Zong 200431 RCT Animal PLGA
MacLean 20024 PS Human Small bowel obstruction
Margenthaler 20062 PS Human Small bowel obstruction
RCT = randomised controlled trial; PS = prospective non-randomised controlled study.
Table 2. Adjuvant therapy options
1) Pharmacological agents
(a) Streptokinase
(b) Recombinant tissue plasminogen activator
(Alteplase)
(c) Antioxidants (vitamin E)
2) Mechanical barriers
(a) Sodium hyaluronate + phosphate-buffered saline
(Sepracoat, Genzyme, USA)
(b) Oxidised regenerated cellulose (Interceed, Johnson &
Johnson, Canada)
(c) Sodium hyaluronate + carboxymethylcellulose-based
bioresorbable membrane (Seprafilm, Genzyme, USA)
(d) Poly(lactide-co-glycolide)-based membranes
(e) Collagen foil + polypropylene mesh (TissuFoil E,
Baxter, Germany)
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study.11 It was also demonstrated that rt-PA could be
delivered as a gel to delay its release and absorption, as
similar to streptokinase rt-PA is rapidly absorbed into the
peritoneal cavity.11 However, there were risks of postoper-
ative haemorrhage and delays in wound healing associ-
ated with this approach.11 Compared with streptokinase,
rt-PA has similar effects on adhesion reduction but strep-
tokinase has lower risks of complications. Both pharma-
cological agents were only tested on animals and clinical
trials are needed to validate its use in humans.
Antioxidants
Reactive oxygen species (ROS) are produced in a hyper-
oxic environment and during the ischaemic/reperfusion
process. The ROS activity is deleterious for cells. During
laparotomy, the partial pressure of oxygen (150 mmHg) is
higher than the intracellular pO2 (5–40 mmHg) and this
explains the increase in ROS. ROS scavengers such as
antioxidant enzymes and antioxidant molecules can help
balance the ROS activity and toxicity.15 The use of these
ROS scavengers was shown to reduce adhesion formation
following open surgery in animal studies.15 Vitamin E, an
antioxidant molecule, has been shown to exhibit addi-
tional anti-inflammatory effects. It also has the ability to
inhibit fibroblasts and platelet adhesion and release.16 In
an experimental model in rats, de la Portilla et al found
that intraperitoneal administration of vitamin E reduced
30–90% of adhesions.16 Vitamin E absorption was only
20–60% orally, but when applied intraperitoneally, there
was a reduction in 80% of adhesions.16 The study on ROS
leading adhesion formation is in its preliminary stages.
The trials available on this subject are limited but the
early results are promising.
Mechanical barrier adjuvant therapy
A number of natural and synthetic graft materials have
been employed in an effort to reduce adhesion formation
between traumatised surfaces. These barriers are placed
over traumatised tissues at the conclusion of surgery in
order to separate tissue surfaces. The ideal barrier, besides
being safe and effective, should persist during the critical
remesothelialisation phase, stay in place without sutures
or staples, remain active in the presence of blood and 
be biodegradable. Solid barriers in particular can be used
intra-abdominally for haemostasis and has also been
examined in the context of adhesion prevention.6 These
barriers are shown to be efficacious in preventing surgical
adhesions. They are primarily designed to prevent adhe-
sions between the bowel and the anterior abdominal 
incision.17
Sodium hyaluronate combined with 
phosphate-buffered saline
Hyaluronic acid is a naturally occurring glycosaminogly-
can and a major component of the extracellular matrix. 
It coats serosal surfaces and provides a certain degree of
protection from serosal desiccation.18 Sepracoat (Genzyme,
USA), a combination of hyaluronic acid with phosphate-
buffered saline, has been found to effectively reduce sero-
sal damage, inflammation and postsurgical adhesions in
animal models.19 In a prospective randomised placebo
controlled trial on patients who underwent laparotomy
for gynaecological procedures and subsequent lapa-
roscopy to assess the severity of intraperitoneal adhe-
sions, Sepracoat was found to significantly decrease the
incidence, extent, and severity of de novo adhesions.20
Sepracoat significantly increased the percentage of patients
who were free of de novo adhesion formation to 13.1%,
compared to 4.6% in patients treated with a placebo.20
The solution is ideal in terms of even distribution and
contact with the peritoneal surfaces but in practice, the
fluid form is uncomfortable for the patient and is associ-
ated with side effects such as pulmonary and perineal
oedema.6
Oxidised regenerated cellulose
Oxidised regenerated cellulose or Interceed (Johnson &
Johnson, Canada), has been shown in both animal and
human studies to reduce adhesion formation by forming
a barrier and physically separating adjacent raw peri-
toneal surfaces. It becomes a gel within eight hours and 
is completely cleared from the body within 28 days.21
Interceed reduced the incidence, extent and severity of
postoperative pelvic adhesions but did not completely
prevent them.22 In an a rabbit uterine horn model, the
application of Interceed together with heparin signifi-
cantly reduced adhesion scores.21 However, this reduction
did not reach statistical significance when compared to
untreated individuals in human studies.1 Furthermore, 
to achieve its optimal effect, the use of oxidised regener-
ated cellulose barriers requires the absence of free fluid
within the peritoneum. Absolute haemostasis and com-
plete removal of excessive peritoneal fluid are the main
technical difficulties.21,22
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Sodium hyaluronate/carboxymethylcellulose-based
bioresorbable membrane
Seprafilm (Genzyme, USA) is a bioresorbable membrane
containing sodium hyaluronate/carboxymethylcellulose.
It becomes a hydrophilic gel within approximately 24
hours after placement and provides a protective coat
around traumatised tissue for up to 7 days during re-
mesothelialisation.23 The material is completely cleared
from the body within 28 days and, unlike Interceed, it can
be used in the presence of blood.23 The effect of the mem-
brane on wound healing, and a series of challenge tests to
determine its toxicology, immunogenicity, and biocom-
patibility was described in an animal study.24 Seprafilm
was found to reduce the number of caecal adhesions sig-
nificantly. The treated group had a significantly larger
proportion of adhesion-free animals (72%) than the un-
treated group (28%) in post-caecal abrasion or abdominal
sidewall injury.24 Seprafilm maintains its efficacy when
used with excessive irrigation solutions, when layered,
and under ischaemic conditions.24 These are the technical
advantages that Seprafilm have over Interceed.
The effect of seprafilm on intraperitoneal adhesions
was studied in a multi-centre prospective double blind
randomised controlled trial on patients who underwent
total procto-colectomy and ileal-pouch anal anastomosis
with diverting loop ileostomy for ulcerative colitis or famil-
ial polyposis. One hundred and eighty-three patients were
randomised to receive or not to receive the hyaluronate/
carboxymethylcellulose membrane over the midline inci-
sion. The incidence, extent and severity of the midline
adhesions were evaluated by laparoscopy during the time
of ileostomy closure. Of the 175 assessable patients, 6% 
of the 90 patients in the control group were free of 
adhesions while 51% of the 85 patients who received
hyaluronate/carboxymethylcellulose membranes were
adhesion free. The mean percent length of the incision
involved by adhesions as well as the incidence of dense
adhesions were also significantly greater in the control
group.25 The incidences of specific adverse events were
not different in the two groups.
In another study on patients who underwent Hartmann
procedure for sigmoid diverticulitis or obstructing can-
cer, 71 patients were randomised to receive and not to
receive Seprafilm over the midline incision. Of the 42
assessable patients, the overall incidence of adhesions
does not differ significantly between the control group
and the patients who received intraperitoneal placement
of Seprafilm.26 However, the severity of adhesions over
the midline incision and the pelvic area was significantly
reduced in patients treated with Seprafilm.26
The ability of Seprafilm to reduce intestinal obstruction
was investigated in a multi-centre randomised controlled
trial on patients who underwent intestinal resection. In
the study, 1,791 patients who underwent open resection
of the small bowel, colon or rectum were randomised into
Seprafilm or no treatment after the operation. Of the
1,701 patients evaluated for the outcome of intestinal
obstruction, there was no difference in the incidences of
first intestinal obstruction between the two groups (12%
versus 12%). However, the incidence of adhesive bowel
obstruction which required reoperation was 1.8% in the
Seprafilm group while that in the control group was 3.4%.27
The difference was statistically significant (p < 0.05) and
treatment with Seprafilm was the only predicting factor
associated with a reduction in the incidence of adhesive
obstruction that required reoperation.
Another novel addition to Seprafilm has been studied
recently. By adding a glycerol compound to the formula,
there was an improvement in the product’s tensile
strength and memory.28 The study involved patients with
ulcerative colitis or familial polyposis undergoing restor-
ative proctocolectomy and ileal pouch-anal anastomosis
with diverting loop ileostomy.28 There were fewer patients
who developed small bowel adhesions (treated=53% versus
control = 73%) and omentum adhesions (treated = 40%
versus control = 65%) when using the novel Seprafilm for-
mula.28 Furthermore, there was a reduction in the severity
of adhesions in the treated group.28
Drawbacks to Seprafilm included a higher incidence
of fistula formation (Seprafilm group: 2% versus control
group: < 1%) when Seprafilm was wrapped around an
anastomosis or intestinal suture line. There was also a
higher incidence of impaired wound healing and infec-
tions (e.g. abscess formation peritonitis) associated with
the use of Seprafilm.25,29 Wrapping the suture or staple
line of a fresh bowel anastomosis with Seprafilm should
also be avoided due to an increased risk of an anastomotic
leak.25,29
The use of adhesion reducing substance is effective
but costly. Although complications due to adhesion for-
mation poses a large economic burden (US$1.18 billion a
year), the cost of the barrier methods is also high.30 There
are so far no cost effectiveness studies on the use of these
barrier methods.
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Poly(lactide-co-glycolide)-based membranes (PLGA)
Currently, there have been studies on the prevention of
postoperative abdominal adhesions by novel nanostruc-
tured barriers. These electrospun bioabsorbable nanofi-
brous poly(lactide-co-glycolide)-based membranes (PLGA)
are made by electrospinning technology to fabricate
unwoven mats or nanofibres.31 In an animal study with
the rats undergoing midline celiotomy, caecal adhesions
were reduced from 78% (control) to 50% (PLGA group).31
Caecal adhesions were further reduced to 22% when using
the PLGA with an addition of hydrophilic co-polymer
poly(ethylene glycol/poly(D,L-lactide) (PLGA/PEG-PLA).31
It is postulated that the addition of hydrophilic co-polymer
to PLGA can make the barrier more stable because it over-
comes the shrinkage problem caused by the hydrophobic
nature of PLGA.31 A locally controlled delivery system of
antibiotics further improves the anti-adhesion property.
After addition of electrospun antibiotics (cefoxitin sodium
in the study), the PLGA group with antibiotics had adhe-
sions in 25% of cases, compared to 50% with PLGA
alone.31 Combination of the PGLA/PEG-PLA with antibi-
otics was able to achieve a zero adhesion rate.31 It has been
postulated that the use of antibiotics can reduce bacterial
load and subsequent inflammation on the wound site.
However, this theory is controversial. In fact, the use of
intra-abdominal antibiotics may be associated with an
increased severity of adhesions.31
Collagen foil, TissuFoil E
Collagen foil used in combination with polypropylene
mesh for the repair of experimental abdominal wall
defects also reduced the formation of adhesions in an ani-
mal study. TissuFoil E (Baxter, Germany) showed signifi-
cantly less severe and also less extensive adhesions when
compared with using polypropylene mesh alone.17 There
were less severe inflammatory reactions found histologi-
cally after collagen foil was added to polypropylene mesh.17
Similarly to PLGA membranes, TissuFoil E has signifi-
cant anti-adhesion properties. However, these membranes
have no clinical evidence supporting their use in humans
at the moment.
Conclusion
Adjuvant therapy is well studied with the engineering 
of many novel mechanical barriers. However, only a few
barrier methods are currently approved by the Food and
Drug Administration (FDA). Seprafilm appears to have
the best adhesion reduction results in clinical studies.
However, it has significant drawbacks due to its cost and
higher complication rates. Many novel pharmacological
and barrier methods such as slow release streptokinase,
antioxidant molecules, poly(lactide-co-glycolide)-based
membranes and TissuFoil E were found to reduce adhe-
sion significantly in animal studies but there are as yet no
clinical studies to support their use in patients. Further
studies will be required to validate these adjuvant thera-
pies but the results based on currently available evidence
are promising.
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